A widely used and generic medicine used as an anti-diabetic has managed in the experimental phase to decrease the risks of long covid by 40% in more than 500 patients. The study just published in the 'Lancet Infectious Disease journal' is already considered a milestone, albeit with the need for further long-term analysis.
In the tests conducted at the University of Minnesota on 564 non-severe and non-hospitalized covid patients, the use of metformin for 14 days has shown to lead to 40% less diagnosis.